Policy Statement-Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia
Policy Statement-Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia
复制标题
DOI：
10.1542/peds.2010-1534
复制
发表时间：
2010-10-01
期刊：
影响因子：
8
通讯作者：
Watterberg, Kristi L.
中科院分区：
文献类型：
--
作者：
Watterberg, Kristi L.;Papile, Lu-Ann;Watterberg, Kristi L.
本修订声明的目的是回顾有关使用产后糖皮质激素预防或治疗早产儿支气管肺发育不良的最新信息，并就其使用提出最新建议。高剂量地塞米松（每天 0.5 毫克/公斤）似乎并没有比低剂量提供额外的治疗效果，因此不推荐。证据不足以就其他糖皮质激素剂量和制剂提出建议。临床医生在尝试平衡糖皮质激素治疗与支气管肺发育不良的潜在不良反应时必须使用临床判断。儿科 2010；126：800-808
The purpose of this revised statement is to review current information on the use of postnatal glucocorticoids to prevent or treat bronchopulmonary dysplasia in the preterm infant and to make updated recommendations regarding their use. High-dose dexamethasone (0.5 mg/kg per day) does not seem to confer additional therapeutic benefit over lower doses and is not recommended. Evidence is insufficient to make a recommendation regarding other glucocorticoid doses and preparations. The clinician must use clinical judgment when attempting to balance the potential adverse effects of glucocorticoid treatment with those of bronchopulmonary dysplasia. Pediatrics 2010;126:800-808